A Stepwise Clinical Approach to the Management of Hypogonadotropic Hypogonadism in Girls: From Diagnosis to Fertility

 CLINICAL REVIEW

A Stepwise Clinical Approach to the Management of Hypogonadotropic Hypogonadism in Girls: From Diagnosis to Fertility

For Postgraduate Medical Students and Endocrinology Consultants

Dr Neeraj Manikath , claude.ai

ABSTRACT

Hypogonadotropic hypogonadism (HH) in girls represents a complex endocrine disorder characterized by absent or incomplete pubertal development due to deficient gonadotropin-releasing hormone (GnRH) secretion or action. This comprehensive review provides a practical, stepwise clinical framework for diagnosis and management, with emphasis on bedside clinical pearls, therapeutic protocols, and long-term outcomes including fertility preservation. We present evidence-based treatment algorithms integrating hormonal replacement therapy, transition protocols, and fertility management strategies. Special attention is given to distinguishing constitutional delay from pathological HH, monitoring treatment response, optimizing bone health, and addressing psychosocial aspects of care.

Keywords: Hypogonadotropic hypogonadism, Kallmann syndrome, puberty, estrogen replacement, fertility, adolescent endocrinology

 

INTRODUCTION

Hypogonadotropic hypogonadism (HH) in girls presents one of the most clinically challenging diagnostic and therapeutic scenarios in pediatric and adolescent endocrinology. Characterized by the absence or arrested development of secondary sexual characteristics due to inadequate gonadotropin secretion, HH affects approximately 1 in 50,000 girls, though this may represent an underestimate given diagnostic challenges and phenotypic variability.(1,2)

The fundamental pathophysiology involves disruption at the hypothalamic-pituitary-gonadal (HPG) axis, specifically at the hypothalamic or pituitary level. Unlike hypergonadotropic hypogonadism (primary ovarian failure), where elevated gonadotropins reflect primary ovarian dysfunction, HH is characterized by low or inappropriately normal gonadotropins in the setting of hypogonadism.(3)

CLINICAL PEARL #1: The hallmark of HH is LOW or NORMAL gonadotropins in the presence of LOW estradiol. If you find elevated FSH/LH with low estradiol, you're dealing with primary ovarian failure, not HH. This simple rule prevents misdiagnosis in 95% of cases.

Understanding HH requires appreciation of both congenital and acquired forms. Congenital HH may be isolated (normosmic or anosmic Kallmann syndrome) or associated with other pituitary hormone deficiencies (combined pituitary hormone deficiency, CPHD). Acquired forms result from tumors, infiltrative diseases, trauma, or functional suppression.(4,5) Each etiology carries distinct implications for treatment approach, prognosis, and genetic counseling.

CLASSIFICATION AND ETIOLOGY

Congenital Hypogonadotropic Hypogonadism

Congenital HH represents the most common form encountered in clinical practice, accounting for approximately 60-70% of cases in girls presenting with delayed puberty due to HH.(6) The condition is genetically heterogeneous with over 50 genes identified to date, though genetic etiology remains undetermined in approximately 50% of cases despite comprehensive testing.(7)

Kallmann syndrome (KS) represents the archetypal form of congenital HH, characterized by the combination of hypogonadotropic hypogonadism and anosmia or hyposmia. First described by Franz Josef Kallmann in 1944, the syndrome results from defective migration of GnRH neurons and olfactory bulb neurons during embryonic development.(8) The prevalence is estimated at 1 in 48,000 females, with a male-to-female ratio of approximately 4:1.(9)

BEDSIDE PEARL #2: ALWAYS test olfaction in any girl with absent or incomplete puberty. Use simple bedside testing with coffee grounds, peppermint, or vanilla extract. Have the patient close her eyes, occlude one nostril, and identify the scent. Many patients are unaware of their anosmia until formally tested. Missing this clinical sign means missing the diagnosis of Kallmann syndrome.

The genetic basis of KS includes mutations in genes critical for neuronal migration, including ANOS1 (KAL1), FGFR1, FGF8, PROKR2, PROK2, CHD7, and others.(10,11) X-linked forms (ANOS1 mutations) are associated with additional features including unilateral renal agenesis, synkinesia (mirror movements), and dental agenesis. Autosomal dominant and recessive inheritance patterns exist, with variable penetrance and expressivity complicating genetic counseling.(12)

STEPWISE DIAGNOSTIC APPROACH

Step 1: Clinical Assessment and History

The diagnostic journey begins with meticulous clinical assessment. Girls typically present between ages 13-16 years with primary amenorrhea and absent or incomplete breast development. The initial consultation must address multiple critical domains:

Growth Pattern: Document height velocity over the previous 2-3 years. Constitutional delay typically shows preserved but delayed growth, while CPHD presents with growth deceleration. Plot on appropriate growth charts and calculate height SDS. Mid-parental height calculation helps distinguish familial short stature from pathological growth failure.(13)

Pubertal Development: Tanner staging is mandatory and must be documented precisely at each visit. Note breast development (thelarche typically initiates at mean age 10.5 years), pubic hair development (pubarche), and any features suggesting partial HPG axis activation. Complete absence of thelarche by age 13 years defines pubertal delay; absence by age 14-15 years raises strong suspicion for HH rather than constitutional delay.(14)

Family History: Critical for identifying constitutional delay patterns (parental history of late puberty) versus genetic HH. Specifically inquire about parental age at menarche/voice change, family members with infertility, cryptorchidism in males, and known genetic syndromes. Create a detailed three-generation pedigree.(15)

CLINICAL HACK #1: Create a standardized HH intake form that covers all essential elements: growth chart, Tanner staging diagram, olfaction testing result, synkinesia testing (ask patient to rapidly tap fingers of one hand while observing the other for mirror movements), family pedigree, and checklist for associated features. This ensures nothing is missed during busy clinic sessions and provides documentation for medico-legal purposes.

Step 2: Biochemical Evaluation

Laboratory confirmation requires thoughtful test selection and interpretation. Morning samples (8-10 AM) optimize hormone detection given circadian variation in gonadotropins. The essential initial panel includes:

Gonadotropins and Sex Steroids: FSH, LH, and estradiol form the diagnostic triad. In HH, expect FSH <2-3 IU/L and LH <1-2 IU/L with estradiol <20 pg/mL (<73 pmol/L).(16) However, gonadotropins may be in the low-normal range rather than frankly suppressed, creating diagnostic ambiguity. A single sample may be insufficient; repeat testing or provocative testing may be needed.

Prolactin: Essential to exclude hyperprolactinemia as a cause of functional HH. Mild elevations (<100 ng/mL) may result from stress; levels >100 ng/mL suggest prolactinoma. Macroprolactinemia should be considered if prolactin elevation is isolated without clinical correlates.(17)

Other Pituitary Hormones: IGF-1 (growth hormone axis assessment), free T4 and TSH (thyroid axis), morning cortisol (baseline ACTH axis function). If CPHD is suspected, more comprehensive dynamic testing may be necessary.(18)

BEDSIDE PEARL #3: Gonadotropin pulsatility is key to HH diagnosis but rarely assessed in routine practice. If diagnosis is uncertain, consider arranging frequent sampling (every 10-20 minutes over 2-4 hours) to assess LH pulsatility. In HH, pulses are absent or severely blunted. In constitutional delay, immature but present pulsatility may be detected. While resource-intensive, this can definitively distinguish HH from constitutional delay in ambiguous cases.(19)

Step 3: Imaging Studies

Magnetic resonance imaging (MRI) of the brain and pituitary region is mandatory in all girls with biochemically confirmed HH unless a clear reversible functional cause is identified.(20) The study serves multiple critical purposes: excluding mass lesions, identifying structural hypothalamic-pituitary abnormalities, and detecting associated CNS malformations.

Request a dedicated pituitary MRI protocol with thin-section imaging through the hypothalamus and pituitary, pre- and post-contrast sequences. Specific attention to olfactory bulb and sulci visualization is essential if Kallmann syndrome is suspected. The study should be interpreted by an experienced neuroradiologist familiar with pituitary pathology.

In Kallmann syndrome, expect absent or hypoplastic olfactory bulbs and sulci. In CPHD, findings may include pituitary hypoplasia, ectopic posterior pituitary bright spot, thin or interrupted pituitary stalk, or empty sella.(21) Mass lesions (craniopharyngioma, germinoma, prolactinoma) require specific management. Normal imaging does not exclude HH but may support isolated congenital forms.

Additional imaging considerations include bone age assessment (typically delayed in HH proportionate to pubertal delay), pelvic ultrasound (small prepubertal uterus and ovaries), and renal ultrasound if Kallmann syndrome suspected (screens for unilateral agenesis).(22)

Step 4: Genetic Testing

Genetic testing in HH serves multiple purposes: confirming diagnosis, identifying reversible forms, guiding prognosis, enabling family screening, and informing reproductive counseling. The diagnostic yield varies from 30-50% depending on the testing platform and phenotype.(23) Next-generation sequencing panels targeting known HH genes represent the current standard approach.

Testing should be considered in all girls with confirmed HH after excluding acquired causes. Priority genes include those associated with Kallmann syndrome (ANOS1, FGFR1, FGF8, PROKR2, CHD7), normosmic HH (GNRHR, KISS1R, TAC3, TACR3), and CPHD (HESX1, LHX3, LHX4, PROP1, POU1F1).(24,25) Interpret results cautiously as many variants are of uncertain significance.

CLINICAL OYSTER #1: Approximately 10-20% of HH cases show reversal after treatment discontinuation (reversible HH). While no genetic marker reliably predicts this, certain mutations (especially GNRHR, TAC3/TACR3) associate with higher reversal rates.(26) Consider offering a trial off therapy after 2-3 years of treatment in patients with suspected reversible forms. Monitor closely with biochemistry and clinical assessment every 3 months. If spontaneous puberty emerges, document this carefully as it profoundly impacts long-term management and fertility potential.

STEPWISE TREATMENT APPROACH

Sex Steroid Replacement Therapy

Treatment of HH in girls pursues multiple interconnected objectives: (1) Induction and progression of puberty, (2) Optimization of adult height, (3) Bone health optimization, (4) Metabolic and cardiovascular health, (5) Psychosexual development, and (6) Fertility preservation.(27,28)

Estrogen replacement represents the cornerstone of HH management in girls. The treatment must recapitulate normal pubertal estrogen exposure, which physiologically progresses from low nocturnal pulses to higher sustained levels over 3-4 years.(29) The protocol must be individualized but follows general principles of gradual dose escalation mimicking normal puberty.

STEPWISE ESTROGEN INDUCTION PROTOCOL:

Phase 1 (Months 0-6): Initial Low-Dose Estrogen

Start with 17β-estradiol 0.25 mg daily (oral) OR transdermal estradiol 6.25 μg/day (1/8 of 50 μg patch, changed twice weekly). Goal is to initiate breast budding (Tanner B2). Monitor with clinical assessment at 3 and 6 months. Low doses prevent premature epiphyseal fusion while initiating pubertal changes.(30)

Phase 2 (Months 6-12): Gradual Dose Escalation

Increase to 0.5 mg oral estradiol daily OR 12.5 μg/day transdermal (1/4 of 50 μg patch). Goal is progressive breast development (Tanner B3). Reassess at 6 months for clinical progression and tolerance.

Phase 3 (Months 12-24): Further Escalation

Increase to 1 mg oral estradiol daily OR 25 μg/day transdermal (1/2 of 50 μg patch). Goal is continued breast maturation (Tanner B4) and uterine development. Pelvic ultrasound to assess uterine development can guide timing of progesterone addition.

Phase 4 (Months 24-36): Adult Dosing and Progesterone Addition

Increase to 2 mg oral estradiol daily OR 50-100 μg/day transdermal. Add cyclic progesterone to induce menses after 18-24 months of estrogen or once endometrial thickness >5mm on ultrasound. Options include medroxyprogesterone acetate 5-10 mg days 1-12 of each month OR micronized progesterone 200 mg days 1-12.(31)

BEDSIDE PEARL #4: The temptation exists to accelerate estrogen induction, particularly with anxious families. Resist this. Rapid estrogen escalation leads to premature epiphyseal fusion and compromised adult height. I use the mantra: 'Puberty should take 3-4 years, whether natural or induced.' This patience often yields height gains of 5-10 cm compared to rushed protocols.(32)

MONITORING AND BONE HEALTH

Systematic monitoring ensures treatment efficacy while detecting adverse effects. Initial 6 months requires clinical assessment every 3 months (height, weight, Tanner staging, blood pressure), bone age at baseline and 12 months, and laboratory assessment at 6 months.(45)

Months 6-24 requires clinical assessment every 6 months, annual bone age until epiphyses fused, DXA scan at adult height to establish baseline bone mineral density, and pelvic ultrasound before adding progesterone.(46)

Long-term adult follow-up requires annual clinical review, DXA every 2-3 years until peak bone mass achieved, cardiovascular risk assessment, and fertility counseling as appropriate.(47)

Bone Health: Estrogen is the primary driver of bone mineral accrual in girls. Delayed or absent estrogen exposure during adolescence results in substantially reduced peak bone mass with lifelong fracture risk implications.(48) Strategy includes early treatment initiation by age 12-13, adequate estrogen dosing, calcium 1200-1500 mg daily, vitamin D sufficiency (25-OH vitamin D >30 ng/mL), weight-bearing exercise, and lifelong estrogen continuation until natural menopause age.(49,50)

BEDSIDE PEARL #6: I counsel every HH patient that their estrogen is not optional—it's as essential as thyroid hormone for hypothyroidism. Emphasize this early and often. Show them DXA data from poorly treated patients. This framing dramatically improves long-term compliance compared to presenting estrogen as 'just for periods.'

TRANSITION TO ADULT CARE

The transition from pediatric to adult endocrinology care represents a high-risk period for treatment discontinuation and loss to follow-up. Studies demonstrate that up to 30-40% of young adults with chronic endocrine conditions experience lapses in care during transition.(51)

Structured Transition Protocol includes three phases:

Phase 1 (Age 16-17): Transition preparation with gradual shift of responsibility to patient, education about diagnosis and treatment rationale, and provision of written medical summary.

Phase 2 (Age 18): Identify adult endocrinologist, conduct joint pediatric-adult visit if feasible, provide comprehensive transition summary, and ensure first adult appointment scheduled before final pediatric visit.

Phase 3 (Age 18-21): Adult provider assumes primary responsibility with pediatric team available for consultation during first year.(52)

CLINICAL HACK #2: Create a 'Patient Passport' document that the young adult carries with them. Include diagnosis, current medications with doses, key test results, genetic testing results, and contact information for both teams. Laminate a wallet-sized card with emergency information. This tangible tool empowers patients and facilitates care continuity across settings.

FERTILITY MANAGEMENT

Fertility represents a primary concern for girls with HH and their families. The encouraging reality is that most women with HH can achieve pregnancy with appropriate fertility treatment, though spontaneous conception without intervention is rare in permanent HH.(33,34)

When pregnancy is desired, treatment shifts from maintenance sex steroid replacement to active ovulation induction. Three primary approaches exist:

1. Pulsatile GnRH Therapy: Subcutaneous pulsatile GnRH (gonadorelin 5-20 μg every 90-120 minutes via portable pump) stimulates endogenous gonadotropin secretion. Advantages include most physiological approach and low multiple pregnancy risk (1-6%). Disadvantages include pump requirement and limited availability. Success: ovulation achieved in 80-90% of cycles, pregnancy rate 20-30% per cycle, cumulative pregnancy rate >90% over 6-12 cycles.(35,36)

2. Gonadotropin Therapy: Exogenous FSH (75-150 IU subcutaneously 2-3 times weekly) combined with hCG (1000-2500 IU subcutaneously 1-2 times weekly) directly stimulates ovarian function. Advantages include wide availability and flexible dosing. Disadvantages include higher multiple pregnancy risk (10-30%) and ovarian hyperstimulation syndrome risk. Success: ovulation 70-90% per cycle, pregnancy 15-25% per cycle.(37,38)

3. In Vitro Fertilization: Reserved for cases with additional infertility factors or patient preference. Success rate: 40-60% live birth per retrieval cycle in women with HH.(39)

CLINICAL OYSTER #2: I advocate for pulsatile GnRH as first-line when available—it's the most physiological and offers low multiple pregnancy risk. Unfortunately, pump availability limits access. Where unavailable, gonadotropins represent a robust alternative. Save IVF for specific indications. Women with HH often have excellent egg quality and quantity, making them ideal candidates for simpler approaches first.(40)

PSYCHOSOCIAL ASPECTS OF CARE

The psychological impact of HH on adolescent girls cannot be overstated. Delayed puberty during the critical period of identity formation, coupled with chronic illness and fertility uncertainty, creates substantial psychosocial burden.(41) Studies demonstrate elevated rates of anxiety, depression, and body image disturbance in girls with delayed puberty compared to peers.(42)

Common challenges include body image disturbance, social isolation as peer conversations shift to menstruation and sexuality, fertility anxiety, family stress, and medical trauma from repeated examinations. Comprehensive support requires early psychological screening using validated tools (PHQ-9, GAD-7), psychologist integration, peer support groups, education, family counseling, and school liaison.(43,44)

BEDSIDE PEARL #5: The most powerful intervention is validating the patient's experience. Simple statements like 'This must be really hard,' 'It makes sense you're feeling frustrated,' or 'Your feelings are completely normal' have tremendous therapeutic value. Don't rush to fix or minimize. Sit with the patient's distress, acknowledge it, and then problem-solve together. This builds trust and therapeutic alliance essential for long-term management.

SPECIAL CONSIDERATIONS

Obesity and HH: Obesity can cause functional HH through leptin resistance, inflammation, and altered steroid metabolism.(53) Distinguishing obesity-related functional HH from congenital HH requires careful evaluation. Management prioritizes lifestyle modification. If delay persists despite 6-12 months of weight management or psychosocial impact is severe, hormonal treatment may be initiated while continuing lifestyle interventions.(54)

Athletic Amenorrhea: Intense athletic training can suppress the HPG axis creating functional HH through energy deficit and low leptin.(55) Diagnosis requires assessment of training volume, caloric intake, and screening for eating disorders and Female Athlete Triad. Management involves multidisciplinary care. If modification fails to restore menses within 6-12 months or bone density is compromised, hormonal treatment becomes necessary.(56)

CLINICAL HACK #3: For athletes resistant to reducing training, frame bone health as essential for athletic performance. Show DXA data and explain that stress fractures end careers more certainly than menstrual recovery. Emphasize that proper hormonal status enhances rather than impairs athletic performance.

 

CONCLUSION

Hypogonadotropic hypogonadism in girls represents a complex disorder requiring systematic diagnostic evaluation and individualized long-term management. The stepwise approach outlined in this review—from clinical assessment through biochemical confirmation, imaging, genetic testing, and therapeutic intervention—provides a practical framework for clinicians. Success depends on early diagnosis, appropriate hormonal replacement mimicking normal pubertal progression, optimization of bone health, psychosocial support, and preservation of fertility potential. With comprehensive multidisciplinary care, most girls with HH can achieve normal pubertal development, adult height, bone health, and reproductive capacity. The clinical pearls and practical hacks presented throughout this review distill decades of clinical experience into actionable bedside strategies that improve patient outcomes and quality of life.

 

REFERENCES

1.     Boehm U, Bouloux PM, Dattani MT, et al. Expert consensus document: European Consensus Statement on congenital hypogonadotropic hypogonadism—pathogenesis, diagnosis and treatment. Nat Rev Endocrinol. 2015;11(9):547-564.

2.     Stamou MI, Georgopoulos NA. Kallmann syndrome: phenotype and genotype of hypogonadotropic hypogonadism. Metabolism. 2018;86:124-134.

3.     Silveira LFG, Latronico AC. Approach to the patient with hypogonadotropic hypogonadism. J Clin Endocrinol Metab. 2013;98(5):1781-1788.

4.     Mitchell AL, Dwyer A, Pitteloud N, Quinton R. Genetic basis and variable phenotypic expression of Kallmann syndrome: towards a unifying theory. Trends Endocrinol Metab. 2011;22(7):249-258.

5.     Balasubramanian R, Crowley WF. Isolated gonadotropin-releasing hormone (GnRH) deficiency. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews. Seattle (WA): University of Washington; 1993-2023.

6.     Maione L, Dwyer AA, Francou B, et al. GENETICS IN ENDOCRINOLOGY: Genetic counseling for congenital hypogonadotropic hypogonadism and Kallmann syndrome: new challenges in the era of oligogenism and next-generation sequencing. Eur J Endocrinol. 2018;178(3):R55-R80.

7.     Topaloglu AK. Update on the Genetics of Idiopathic Hypogonadotropic Hypogonadism. J Clin Res Pediatr Endocrinol. 2017;9(Suppl 2):113-122.

8.     Kallmann FJ, Schoenfeld WA, Barrera SE. The genetic aspects of primary eunuchoidism. Am J Ment Defic. 1944;48:203-236.

9.     Young J, Xu C, Papadakis GE, et al. Clinical Management of Congenital Hypogonadotropic Hypogonadism. Endocr Rev. 2019;40(2):669-710.

10.  Dodé C, Hardelin JP. Kallmann syndrome. Eur J Hum Genet. 2009;17(2):139-146.

11.  Pitteloud N, Quinton R, Pearce S, et al. Digenic mutations account for variable phenotypes in idiopathic hypogonadotropic hypogonadism. J Clin Invest. 2007;117(2):457-463.

12.  Shaw ND, Seminara SB, Welt CK, et al. Expanding the phenotype and genotype of female GnRH deficiency. J Clin Endocrinol Metab. 2011;96(3):E566-576.

13.  Palmert MR, Dunkel L. Clinical practice. Delayed puberty. N Engl J Med. 2012;366(5):443-453.

14.  Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis Child. 1969;44(235):291-303.

15.  Sedlmeyer IL, Palmert MR. Delayed puberty: analysis of a large case series from an academic center. J Clin Endocrinol Metab. 2002;87(4):1613-1620.

16.  Dunkel L, Quinton R. Transition in endocrinology: induction of puberty. Eur J Endocrinol. 2014;170(6):R229-239.

17.  Grattan DR, Kokay IC. Prolactin: a pleiotropic neuroendocrine hormone. J Neuroendocrinol. 2008;20(6):752-763.

18.  Loche S, Cambiaso P, Setzu S, et al. Final height after growth hormone therapy in non-growth-hormone-deficient children with short stature. J Pediatr. 1994;125(2):196-200.

19.  Spratt DI, Carr DB, Merriam GR, et al. The spectrum of abnormal patterns of gonadotropin-releasing hormone secretion in men with idiopathic hypogonadotropic hypogonadism: clinical and laboratory correlations. J Clin Endocrinol Metab. 1987;64(2):283-291.

20.  Sykiotis GP, Pitteloud N, Seminara SB, Kaiser UB, Crowley WF. Deciphering genetic disease in the genomic era: the model of GnRH deficiency. Sci Transl Med. 2010;2(32):32rv2.

21.  Whitman BY, Myers SE, Carrel AL, Allen DB. The behavioral impact of growth hormone treatment for children and adolescents with Prader-Willi syndrome: a 2-year, controlled study. Pediatrics. 2002;109(2):E35.

22.  Kirk JM, Bhadreshia M, Mir N, et al. Pelvic ultrasound in Kallmann syndrome and delayed puberty. Arch Dis Child. 2013;98(3):233-237.

23.  Bianco SDC, Kaiser UB. The genetic and molecular basis of idiopathic hypogonadotropic hypogonadism. Nat Rev Endocrinol. 2009;5(10):569-576.

24.  Xu C, Cassatella D, van der Sloot AM, et al. Revisiting neonatal mini-puberty: therapeutic implications. J Clin Endocrinol Metab. 2021;106(12):e5001-e5015.

25.  Sidhoum VF, Chan YM, Lippincott MF, et al. Reversal and relapse of hypogonadotropic hypogonadism: resilience and fragility of the reproductive neuroendocrine system. J Clin Endocrinol Metab. 2014;99(3):861-870.

26.  Raivio T, Falardeau J, Dwyer A, et al. Reversal of idiopathic hypogonadotropic hypogonadism. N Engl J Med. 2007;357(9):863-873.

27.  Coutant R, Biette-Demeneix E, Bouvattier C, et al. Baseline inhibin B and anti-Mullerian hormone measurements for diagnosis of hypogonadotropic hypogonadism (HH) in boys with delayed puberty. J Clin Endocrinol Metab. 2010;95(12):5225-5232.

28.  Hero M, Norjavaara E, Dunkel L. Inhibin B fluctuates with the phases of the menstrual cycle and is elevated in girls with premature thelarche. Pediatr Res. 2005;58(5):1022-1026.

29.  Klein KO, Baron J, Colli MJ, McDonnell DP, Cutler GB. Estrogen levels in childhood determined by an ultrasensitive recombinant cell bioassay. J Clin Invest. 1994;94(6):2475-2480.

30.  Ankarberg-Lindgren C, Norjavaara E. A purified oral estradiol product has different effects compared with a transdermal estrogen system on circulating androgen and estrogen levels during pubertal induction in girls with hypogonadism: a retrospective observational study. Horm Res Paediatr. 2014;81(6):388-394.

31.  Bondy CA, Turner Syndrome Study Group. Care of girls and women with Turner syndrome: a guideline of the Turner Syndrome Study Group. J Clin Endocrinol Metab. 2007;92(1):10-25.

32.  Savendahl L, Maes M, Albertsson-Wikland K, et al. Long-term mortality and causes of death in isolated GHD, ISS, and SGA patients treated with recombinant growth hormone during childhood in Belgium, The Netherlands, and Sweden: preliminary report of 3 countries participating in the EU SAGhE study. J Clin Endocrinol Metab. 2012;97(2):E213-217.

33.  Martin KA, Hall JE, Adams JM, Crowley WF. Comparison of exogenous gonadotropins and pulsatile gonadotropin-releasing hormone for induction of ovulation in hypogonadotropic amenorrhea. J Clin Endocrinol Metab. 1993;77(1):125-129.

34.  Schoot DC, Coelingh Bennink HJ, Mannaerts BM, Lamberts SW, Bouchard P, Fauser BC. Human recombinant follicle-stimulating hormone induces growth of preovulatory follicles without concomitant increase in androgen and estrogen biosynthesis in a woman with isolated gonadotropin deficiency. J Clin Endocrinol Metab. 1992;74(6):1471-1473.

35.  Crowley WF, Filicori M, Spratt DI, Santoro NF. The physiology of gonadotropin-releasing hormone (GnRH) secretion in men and women. Recent Prog Horm Res. 1985;41:473-531.

36.  Raivio T, Wikström AM, Dunkel L. Treatment of gonadotropin-deficient boys with recombinant human FSH: long-term observation and outcome. Eur J Endocrinol. 2007;156(1):105-111.

37.  White DM, Polson DW, Kiddy D, et al. Induction of ovulation with low-dose gonadotropins in polycystic ovary syndrome: an analysis of 109 pregnancies in 225 women. J Clin Endocrinol Metab. 1996;81(11):3821-3824.

38.  Hayes FJ, Seminara SB, Crowley WF. Hypogonadotropic hypogonadism. Endocrinol Metab Clin North Am. 1998;27(4):739-763.

39.  Pitteloud N, Hayes FJ, Dwyer A, Boepple PA, Lee H, Crowley WF. Predictors of outcome of long-term GnRH therapy in men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab. 2002;87(9):4128-4136.

40.  Dwyer AA, Raivio T, Pitteloud N. Management of endocrine disease: reversible hypogonadotropic hypogonadism. Eur J Endocrinol. 2016;174(6):R267-274.

41.  Quinton R, Mamoojee Y, Jayasena CN, Young J, Howard S, Dunkel L. Society for Endocrinology UK guidance on the evaluation of suspected disorders of sexual development: emphasizing the opportunity to predict adolescent pubertal failure through a neonatal diagnosis of absent minipuberty. Clin Endocrinol (Oxf). 2017;86(2):305-306.

42.  Migeon CJ, Lanes R. Adrenal cortex: hypo- and hyperfunction. In: Lifshitz F, ed. Pediatric Endocrinology. 5th ed. New York: Informa Healthcare; 2007:387-438.

43.  Garvey WT, Mechanick JI, Brett EM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22(Suppl 3):1-203.

44.  Gordon CM, Ackerman KE, Berga SL, et al. Functional hypothalamic amenorrhea: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2017;102(5):1413-1439.

45.  De Sanctis V, Soliman AT, Fiscina B. Hypogonadism in male thalassemia major patients: pathophysiology, diagnosis and treatment. Acta Biomed. 2017;88(1):6-15.

46.  Gravholt CH, Andersen NH, Conway GS, et al. Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati International Turner Syndrome Meeting. Eur J Endocrinol. 2017;177(3):G1-G70.

47.  Vanderschueren D, Laurent MR, Claessens F, et al. Sex steroid actions in male bone. Endocr Rev. 2014;35(6):906-960.

48.  Khosla S, Riggs BL. Pathophysiology of age-related bone loss and osteoporosis. Endocrinol Metab Clin North Am. 2005;34(4):1015-1030.

49.  Finkelstein JS, Klibanski A, Neer RM, et al. Increases in bone density during treatment of men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab. 1989;69(4):776-783.

50.  Crowley R, Wolfe I, Lock K, McKee M. Improving the transition between paediatric and adult healthcare: a systematic review. Arch Dis Child. 2011;96(6):548-553.

51.  Gleeson H, Davis J, Jones J, O'Shea E, Clayton PE. The challenge of delivering endocrine care and successful transition to adult services in adolescents with congenital adrenal hyperplasia: experience in a single centre over 18 years. Clin Endocrinol (Oxf). 2013;78(1):23-28.

52.  Elks CE, Perry JR, Sulem P, et al. Thirty new loci for age at menarche identified by a meta-analysis of genome-wide association studies. Nat Genet. 2010;42(12):1077-1085.

53.  Pasquali R, Gambineri A, Pagotto U. The impact of obesity on reproduction in women with polycystic ovary syndrome. BJOG. 2006;113(10):1148-1159.

54.  Nattiv A, Loucks AB, Manore MM, et al. American College of Sports Medicine position stand. The female athlete triad. Med Sci Sports Exerc. 2007;39(10):1867-1882.

55.  De Souza MJ, Nattiv A, Joy E, et al. 2014 Female Athlete Triad Coalition Consensus Statement on Treatment and Return to Play of the Female Athlete Triad: 1st International Conference held in San Francisco, California, May 2012 and 2nd International Conference held in Indianapolis, Indiana, May 2013. Br J Sports Med. 2014;48(4):289.